Kyfora Bio will represent Polysciences, Inc.’s product offerings to the bioprocessing market as a maker of specialised chemicals for research, IVD, and medical device applications with a base in Pennsylvania.
Kyfora Bio will concentrate on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies, building on Polysciences’ extensive experience in developing and manufacturing monomers, polymers, microspheres, and specialty reagents for the medical device, diagnostic, and pharmaceutical industries.
A 45,000 square foot cGMP building with administrative offices, R&D labs, production suites, and QC labs for chemical and biological performance testing will be home to Kyfora Bio’s Horsham, Pennsylvania headquarters. The 250,000 square foot Warrington, Pennsylvania campus of Polysciences, which serves as the business’s headquarters and houses manufacturing, R&D, QA/QC, and product storage facilities, is not far from the new location.
“Kyfora Bio reflects Polysciences’ latest commitment to be the partner of choice in supplying key cGMP compliant materials to the cell and gene therapy market. Through Kyfora Bio, we will leverage over 60 years of experience in chemical synthesis along with a state-of-the-art manufacturing facility and 210/211 compliant Quality Management System to assist our customers in bringing life-saving therapies to the patient. Our flexible CDMO business model and deep technical expertise are ideal for those seeking the development and manufacture of novel materials used in discovery, clinical trials, and commercial manufacturing of biotherapeutics”
Scott Knorr, President, Kyfora Bio
